US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

Agenus Inc. - Common Stock (NQ:AGEN)

7.540 -0.030 (-0.40%)
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
From Agenus Inc. & BAP Pharma
Via Business Wire
News headline image
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
From Agenus Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
From Agenus Bio
Via Business Wire
News headline image
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
From Agenus Inc.
Via Business Wire
News headline image
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
From Agenus Bio
Via Business Wire
News headline image
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
From Agenus Bio
Via Business Wire
News headline image
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
From Agenus Bio
Via Business Wire
News headline image
Agenus (AGEN) Q2 2025 Earnings Call Transcript ↗
Agenus (AGEN) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Host First 2026 Stakeholder Webcast
From Agenus Inc.
Via Business Wire
Thursday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
From Agenus Inc.
Via Business Wire
News headline image
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
From Agenus Inc.
Via Business Wire
News headline image
Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗
Agenus (AGEN) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agenus (AGEN) Q1 2025 Earnings Call Transcript ↗
Agenus (AGEN) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗
Agenus (AGEN) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
From Agenus Inc.
Via Business Wire
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
From Agenus Inc.
Via Business Wire
News headline image
AGENUS INC (NASDAQ:AGEN) Reports Mixed Q3 2025 Earnings, Driven by One-Time Gain ↗
Agenus reports mixed Q3 2025 results with a revenue miss but strong clinical progress for its cancer drug BOT/BAL, including a new Phase 3 trial. 
Via Chartmill
News headline image
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
From Agenus Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >